-
???insights.card.a11y.category??? news News
Zealand’s obesity drug shouldn’t disrupt Novo Nordisk-Eli Lilly leadership: Mizuho’s Jared Holz
-
???insights.card.a11y.category??? news News
Capital One and Discover merger could pose risks to Visa and Mastercard, says Dan Dolev
-
???insights.card.a11y.category??? news News
Coinbase rally is setting itself up for a bigger fall when it reports, says Mizuho’s Dan Dolev
-
???insights.card.a11y.category??? news News
Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz
-
???insights.card.a11y.category??? news News
Health care’s underperformance last year sets it up well for 2024, says Mara Goldstein
-
???insights.card.a11y.category??? news News
PayPal slides on Q4 results
-
???insights.card.a11y.category??? news News
Eli Lilly hits record high: Here’s what investors need to know
-
???insights.card.a11y.category??? news News
Tickets Now on Sale for the 2024 Mizuho Americas Open; LPGA Returns to Liberty National, Jersey City, May 13-19, 2024
-
???insights.card.a11y.category??? news News
Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz